Osteomalacia

Should I be getting my vitamin D levels checked?

Retrieved on: 
Monday, October 2, 2023

Australia has seen a surge in vitamin D testing of children, with similar trends reported for adults around the world. GPs are now being urged not to test for vitamin D unnecessarily. So when is low vitamin D a potential concern? And when might you need to get your levels tested?How much vitamin D do we need?Vitamin D also has many other roles, including helping our immune defences and contributing to DNA repair and cell differentiation.

Key Points: 


Australia has seen a surge in vitamin D testing of children, with similar trends reported for adults around the world. GPs are now being urged not to test for vitamin D unnecessarily. So when is low vitamin D a potential concern? And when might you need to get your levels tested?

How much vitamin D do we need?

    • Vitamin D also has many other roles, including helping our immune defences and contributing to DNA repair and cell differentiation.
    • We can thank the sun for most of our vitamin D. A chemical in our skin called 7-dehydrocholesterol is converted to vitamin D after contact with UVB radiation from the sun.
    • While we get some vitamin D also through our diet, this makes a relatively small contribution.
    • It’s difficult to get much more than one-third of our daily vitamin D requirement from diet without supplementation.

Why avoid vitamin D deficiency?

    • Prolonged, severe vitamin D deficiency will lead to softening of bone tissue and cause diseases such as rickets (children) and osteomalacia (adults).
    • However, avoiding low concentrations is likely to be good for many aspects of health, with consistent evidence suggesting benefits for infectious diseases and autoimmune conditions such as multiple sclerosis.

Who is at risk of deficiency?

    • The two main reasons for vitamin D deficiency typically relate to: 1. not getting (enough) vitamin D through sun exposure.
    • Deficiency risk can be high for anyone who is housebound, such as older or disabled people in residential care.
    • The risk of deficiency increases if we always cover our skin carefully by modest cultural dress, and also dark skin pigmentation is known to reduce vitamin D synthesis.

Am I getting enough sun exposure?

    • In Australia, it is possible to get enough vitamin D from the sun throughout the year.
    • Read more:
      Why you need more Vitamin D in the winter

      During winter, catching enough sun can be difficult, especially if you spend your days confined indoors.

    • This is because sunlight exposure can only help produce vitamin D if the UVB rays reach us at the correct angle.

Why does excess vitamin D testing matter?

    • Excessive testing is also a waste of health-care resources, with one single test costing about the same as a years’ worth of vitamin D supplementation.
    • Very often, we can make relatively small changes to our lifestyles to reduce the risks of vitamin D deficiency.

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

Retrieved on: 
Tuesday, September 26, 2023

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive interim safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE, pseudoxanthoma elasticum).

Key Points: 
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.
  • Exploratory biomarker data were collected throughout the study to provide evidence of the potential for disease modification with ongoing treatment with INZ-701.
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • PK properties were consistent with those observed in the Phase 1/2 clinical trial in adults with ENPP1 Deficiency.

Antacids Global Market Report 2023

Retrieved on: 
Monday, February 20, 2023

The global antacids market will grow from $9.19 billion in 2022 to $9.56 billion in 2023 at a compound annual growth rate (CAGR) of 4.0%.

Key Points: 
  • The global antacids market will grow from $9.19 billion in 2022 to $9.56 billion in 2023 at a compound annual growth rate (CAGR) of 4.0%.
  • The regions covered in the antacids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The antacids market research report is one of a series of new reports that provides antacids market statistics, including antacids industry global market size, regional shares, competitors with an antacids market share, detailed antacids market segments, market trends, and opportunities, and any further data you may need to thrive in the antacids industry.
  • This antacids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vitamin D Market is expected to generate a revenue of USD 2.07 Billion by 2030, Globally, at 6.45% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, January 25, 2023

JERSEY CITY, N.J., Jan. 25, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Vitamin D Market" By Analog Type (Vitamin D2, Vitamin D3), By Application (Animal feed & pet food, Functional food & beverages, Personal care), By End-User (Children, Adults, Pregnant Women), and By Geography.

Key Points: 
  • Eggs, sea food like fish, and dairy products all contain vitamin D. Vitamin D also makes the brain and neurological systems strong.
  • Ergocalciferol (vitamin D2) and cholecalciferol are the major two types of vitamin D. (vitamin D3).
  • The "Global Vitamin D Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Vitamin D Market" study report will provide valuable insight with an emphasis on the global market.

Global Vitamin D Market Report 2022: High Adoption of Vitamin D in Developing Markets to Boost Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 22, 2022

The vitamin D market in escalating with the increase in consumption and demand of feed around the world.

Key Points: 
  • The vitamin D market in escalating with the increase in consumption and demand of feed around the world.
  • In addition, increasing consumer concerns regarding maintaining a balanced diet and growing consumer awareness about several diseases caused by vitamin D deficiency will also boost the market of Vitamin D during the forecast period.
  • Food fortification is one of the major trends, which is fueling the vitamin D market in the functional food & beverage industry.
  • Based on applications, the vitamin D market was dominated by the pharmaceutical segment in 2021, in terms of value.

Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

Retrieved on: 
Monday, December 5, 2022

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the publication of an article titled “Estimation of ENPP1 Deficiency Genetic Prevalence Using a Comprehensive Literature Review and Population Databases” in the Orphanet Journal of Rare Diseases. Leading disease experts Carlos Ferreira, M.D., of the National Institutes of Health (NIH) and Frank Rutsch, M.D., of Münster University Children’s Hospital, together with Genomenon, an AI-driven genomics company, analyzed the latest genomics data and found the estimated prevalence of ENPP1 Deficiency to be 1 in 64,000 pregnancies, more than tripling the prior estimate1.

Key Points: 
  • “Our medical field team’s disease awareness, education, and patient identification efforts suggested that the number of patients with ENPP1 Deficiency has been vastly underestimated.
  • “Given the higher prevalence of ENPP1 Deficiency, it becomes obvious that many affected individuals remain undiagnosed.
  • “The prevalence data were gathered using a comprehensive database of genomic evidence, providing an unprecedented view into how many people are born with ENPP1 Deficiency worldwide.
  • INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

New Study Shows Comprehensive Genomic Evidence is Critical for Calculating Rare Disease Prevalence

Retrieved on: 
Thursday, December 15, 2022

ANN ARBOR, Mich., Dec. 15, 2022 /PRNewswire-PRWeb/ -- Genomenon, Inc., an AI-driven genomics company, today announced the publication of a paper in the Orphanet Journal of Rare Diseases that calculates the prevalence of ENPP1 deficiency—a disease claiming more than half of all infants within the first few months of life—to be more than triple the prior estimate. The study, conducted by the Genomenon scientific team and leading disease experts from the National Institutes of Health (NIH) and Münster University Children's Hospital, highlights a core strength of Genomenon's rigorous methodology for identifying and classifying genetic data needed to improve rare disease prevalence calculations.

Key Points: 
  • The study, conducted by the Genomenon scientific team and leading disease experts from the National Institutes of Health (NIH) and Mnster University Children's Hospital, highlights a core strength of Genomenon's rigorous methodology for identifying and classifying genetic data needed to improve rare disease prevalence calculations.
  • "Discovery of this higher prevalence rate aptly demonstrates how our exhaustive knowledgebase of expertly curated genomic evidence supports pharmaceutical companies that are pioneering development of therapies for orphan diseases."
  • Traditional methods for estimating prevalence rely on clinical data, which can be unreliable for rare diseases such as ENPP1 deficiency that are difficult to diagnose.
  • Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer.

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 10, 2022

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2022 and provided recent business highlights.

Key Points: 
  • Preclinical data supporting INZ-701's potential to treat intimal proliferation was featured at the International Vascular Biology Meeting (IVBM) 2022 Annual Meeting in October.
  • Cash Position and Financial Guidance Cash, cash equivalents, and investments were $141.5 million as of September 30, 2022.
  • Research and Development (R&D) Expenses R&D expenses were$12.2 millionfor the quarter ended September 30, 2022, compared to$9.3 millionfor the prior-year period.
  • General and Administrative (G&A) Expenses G&A expenses were$4.7 millionfor the quarter ended September 30, 2022, compared to$4.9 millionfor the prior-year period.

Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial

Retrieved on: 
Thursday, November 3, 2022

Inozyme is facilitating self-administration in the Phase 2 extension portion of the clinical trial after patients complete the 32-day dose evaluation period in the clinic.

Key Points: 
  • Inozyme is facilitating self-administration in the Phase 2 extension portion of the clinical trial after patients complete the 32-day dose evaluation period in the clinic.
  • The ongoing Phase 1/2 open-label clinical trial is expected to enroll up to nine adult patients with ENPP1 Deficiency at sites in North America and Europe.
  • INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
  • INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update

Retrieved on: 
Wednesday, November 2, 2022

NOVATO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2022 and provided a corporate update for the year.

Key Points: 
  • During this period, Ultragenyx will continue to share costs of the Crysvita commercial operating expenses with KKC.
  • Ultragenyx will host a conference call today, Wednesday, November 2, 2022, at 2 p.m. PT/ 5 p.m.
  • ET to discuss the third quarter 2022 financial results and provide a corporate update.
  • Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyxs Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/mycompany/).